In the News

In the News

October 16, 2017
Transplant Tailwinds and Momentum

May 10, 2017

Business Wire
Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting

May 3, 2017

Boston Globe
Magenta Therapeutics gets $50 million in funding

May 2, 2017

Magenta gains $50M Series B, Novartis candidate and new partnership

WSJournal Venture Capital Pro
A $50 Million Bet on Stem-Cell Therapy

Magenta Nabs More Cash, Licenses Drug To Boost Transplant Pipeline

Endpoints News
Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it
Building a biotech: Magenta opens up Chapter 2 with a triple play

April 11, 2017

Nature Biotechnology
Magenta named one of Nature Biotechnology’s top academic spinouts of 2016

November 16, 2016

Tackling blood diseases, immune disorders

Boston Business Journal
Atlas, Third Rock launch new Cambridge biotech with $49M round

Harvard Gazette
Tackling blood diseases, immune disorders

Boston Globe
Two venture firms launch Cambridge biotech with $48.5m in funding

Stem cell startup Magenta launches with $48.5m

WSJ Pro Venture Capital
Magenta Therapeutics Closes $49 for Blood Stem-Cell Therapy

Yahoo Finance
Magenta Therapeutics Announces $48.5M Series A Financing to Transform Stem Cell Transplant for Immune and Blood Diseases

Stem Cell Transplant Startup With Harvard Tech, Magenta Therapeutics, Gets $48.5M

Harvard Spinout Magenta, Other Academics Race Toward Better Stem Cell Transplants

Atlas, Third Rock join forces to launch new stem cell upstart

GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round
Rebooting The Conversation

July 15, 2016

Standing on the shoulders of stem cell gene therapists

July 7, 2016
Standing On The Shoulders Of Stem Cell Gene Therapists: History, Hyperbole And Hope For The Future

March 1, 2016
Entrepreneuring Post-Pharma